89bio to Participate in Upcoming Investor Conferences
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
Management will participate in fireside chats at Citi's 2025 Biopharma Back to School Conference on September 3 at 11:15 AM EDT and the Cantor Global Healthcare Conference on September 4 at 11:30 AM EDT. The company will also conduct one-on-one meetings at the H.C. Wainwright Global Investment Conference on September 8. Webcasts will be available on 89bio's investor website with 30-day replay access.
89bio (Nasdaq: ETNB), azienda biofarmaceutica in fase clinica che sviluppa terapie per malattie epatiche e cardiometaboliche, ha annunciato la partecipazione a tre conferenze per investitori previste a settembre 2025.
La direzione prenderà parte a fireside chat al Citi's 2025 Biopharma Back to School Conference il 3 settembre alle 11:15 EDT e al Cantor Global Healthcare Conference il 4 settembre alle 11:30 EDT. L'azienda terrà inoltre incontri one-to-one all'H.C. Wainwright Global Investment Conference l'8 settembre. I webcast saranno disponibili sul sito per gli investitori di 89bio con replay accessibile per 30 giorni.
89bio (Nasdaq: ETNB), una compañía biofarmacéutica en fase clínica que desarrolla terapias para enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en tres conferencias para inversores en septiembre de 2025.
La dirección participará en charlas tipo fireside en el Citi's 2025 Biopharma Back to School Conference el 3 de septiembre a las 11:15 EDT y en el Cantor Global Healthcare Conference el 4 de septiembre a las 11:30 EDT. La compañía también realizará reuniones individuales en el H.C. Wainwright Global Investment Conference el 8 de septiembre. Los webcasts estarán disponibles en la web de inversores de 89bio con reproducción disponible durante 30 días.
89bio (Nasdaq: ETNB)는 간 및 심장대사 질환 치료제를 개발하는 임상 단계 바이오제약회사로, 2025년 9월에 예정된 세 곳의 투자자 컨퍼런스에 참여한다고 발표했습니다.
경영진은 Citi's 2025 Biopharma Back to School Conference에서 9월 3일 오전 11:15(EDT)에, Cantor Global Healthcare Conference에서는 9월 4일 오전 11:30(EDT)에 파이어사이드 채팅에 참여합니다. 또한 회사는 9월 8일 H.C. Wainwright Global Investment Conference에서 일대일 미팅을 진행합니다. 웹캐스트는 89bio 투자자 웹사이트에서 제공되며 30일간 재생이 가능합니다.
89bio (Nasdaq: ETNB), une société biopharmaceutique en phase clinique développant des traitements pour les maladies hépatiques et cardiométaboliques, a annoncé sa participation à trois conférences investisseurs en septembre 2025.
La direction prendra part à des « fireside chats » lors du Citi's 2025 Biopharma Back to School Conference le 3 septembre à 11h15 EDT et du Cantor Global Healthcare Conference le 4 septembre à 11h30 EDT. La société tiendra également des réunions individuelles lors du H.C. Wainwright Global Investment Conference le 8 septembre. Les webcasts seront accessibles sur le site investisseurs de 89bio avec une rediffusion disponible pendant 30 jours.
89bio (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in klinischer Phase, das Therapien für Leber- und kardiometabolische Erkrankungen entwickelt, hat seine Teilnahme an drei Investorenkonferenzen im September 2025 bekanntgegeben.
Das Management wird an Fireside-Chats beim Citi's 2025 Biopharma Back to School Conference am 3. September um 11:15 Uhr EDT und beim Cantor Global Healthcare Conference am 4. September um 11:30 Uhr EDT teilnehmen. Das Unternehmen führt außerdem Einzelgespräche auf der H.C. Wainwright Global Investment Conference am 8. September. Webcasts sind auf der Investorenseite von 89bio verfügbar und können 30 Tage lang nachgehört werden.
- None.
- None.
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s management will participate in the following investor conferences during the month of September:
| Citi’s 2025 Biopharma Back to School Conference | |
| Format: | Fireside Chat |
| Date: | Wednesday, September 3, 2025 |
| Time: | 11:15 AM EDT |
| Cantor Global Healthcare Conference 2025 | |
| Format: | Fireside Chat |
| Date: | Thursday, September 4, 2025 |
| Time: | 11:30 AM EDT |
| H.C. Wainwright 27th Annual Global Investment Conference | |
| Format: | One-on-one meetings |
| Date: | Monday, September 8, 2025 |
The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The Company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The Company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the Company on LinkedIn.
Investor Contacts:
Annie Chang
89bio, Inc.
investors@89bio.com
Eva Bilange
89bio, Inc.
eva.bilange@89bio.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
When is 89bio (ETNB) presenting at Citi's 2025 Biopharma Conference?
Where can I watch 89bio's (ETNB) investor conference presentations?
Which investor conferences is 89bio (ETNB) attending in September 2025?
What type of company is 89bio (ETNB)?
